Login to Your Account

Fueling up: Auspex files to raise $60M to carry SD-809 to success

By Michael Fitzhugh
Staff Writer

Monday, July 14, 2014

Just five months after raising about $94.8 million in a well-received initial public offering (IPO), Auspex Pharmaceuticals Inc. has priced a new follow-on offering expected to raise an additional $60.6 million to carry a new pivotal trial of its lead candidate, SD-809 (deutetrabenazine), in the movement disorder tardive dyskinesia and to support the company through at least the second quarter of 2016.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription